Adaptive Biotechnologies’ Rubinstein sells $1.49m in shares
#Adaptive Biotechnologies #Julie Rubinstein #Insider Trading #ADPT stock #Stock Options #Market Performance #Earnings Report
📌 Key Takeaways
- Rubinstein sold nearly 93,000 shares worth $1.49 million
- The stock has gained 105% over the past year
- Rubinstein also acquired shares through option exercises
- The company reported strong Q4 earnings exceeding expectations
- Analysts have raised price targets for the stock
📖 Full Retelling
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 92,823 shares of company stock between March 3 and March 5, 2026, for approximately $1.49 million as part of a pre-arranged trading plan. The transactions occurred at prices ranging from $15.49 to $16.60 per share, while the company's stock currently trades at $15.93, having surged 105% over the past year despite analysis suggesting potential overvaluation relative to its fair value estimate. In addition to the sales, Rubinstein exercised stock options to acquire 73,610 shares at prices of $6.55 and $12.14, totaling $721,993, demonstrating continued confidence in the company's future prospects. These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Rubinstein on November 18, 2025, which allows executives to sell shares under predetermined conditions without concerns about insider trading allegations.
🏷️ Themes
Executive Trading, Company Performance, Stock Market
📚 Related People & Topics
Insider trading
Trading using nonpublic information
# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...
Entity Intersection Graph
Connections for Insider trading:
🌐
SEC filing
17 shared
🌐
Restricted stock
4 shared
👤
New York Stock Exchange
3 shared
🌐
EVP
3 shared
🌐
Vice president
3 shared
Mentioned Entities
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil extends weekly gains as Iran conflict rages on, with crude surging around 18% Trump replaces Homeland Security chief Kristi Noem Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) Adaptive Biotechnologies’ Rubinstein sells $1.49m in shares By Insider Trading Published 03/05/2026, 07:55 PM Adaptive Biotechnologies’ Rubinstein sells $1.49m in shares 0 ADPT -3.10% Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT) , sold a total of 92,823 shares of common stock between March 3 and March 5, 2026, for approximately $1.49 million. The sales occurred at prices ranging from $15.49 to $16.60 per share. The stock currently trades at $15.93, up 105% over the past year, though InvestingPro analysis suggests the shares may be overvalued relative to its Fair Value estimate. Investors can explore this and other potentially overvalued stocks for deeper market insights. The Adaptive Biotechnologies executive also acquired shares through the exercise of stock options. On March 3, 4, and 5, Rubinstein exercised options to acquire a total of 73,610 shares of Adaptive Biotechnologies common stock at prices of $6.55 and $12.14, for a total value of $721,993. For comprehensive analysis including additional ProTips and detailed metrics, ADPT is among the 1,400+ US equities covered by InvestingPro’s Pro Research Reports. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. In other recent news, Adaptive Biotechnologies Corp reported impressive fourth-quarter 2025 earnings, surpassing analyst expectations. The company posted an earnings per share of -$0.09, which was a 50% positive surprise compared to the forecasted -$0.18. Revenue also exceeded expectations, reaching $71.7 million,...
Read full article at source